The Experts below are selected from a list of 48 Experts worldwide ranked by ideXlab platform

Dhruv Gupta - One of the best experts on this subject based on the ideXlab platform.

M. K. Singhi - One of the best experts on this subject based on the ideXlab platform.

Lalit Kumar Gupta - One of the best experts on this subject based on the ideXlab platform.

U M Goehring - One of the best experts on this subject based on the ideXlab platform.

  • a phase i randomized trial to assess the effect on Skin Infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test
    British Journal of Dermatology, 2016
    Co-Authors: S D Snape, W Wiggeralberti, U M Goehring
    Abstract:

    SummaryBackground Oral phosphodiesterase (PDE)4 inhibitors have shown efficacy in chronic obstructive pulmonary disease and psoriasis. Objectives To assess the effectiveness, local safety and tolerability, and systemic pharmacokinetics of two topical PDE4 inhibitors, roflumilast and TAK-084, in plaque psoriasis. Methods An intraindividual comparison of six topical products was made in 15 patients aged 18–65 years with stable chronic plaque psoriasis in an investigator-blinded, within-subject randomized study. The products evaluated were calcipotriol 0·005% cream; betamethasone valerate 0·1% (both in their marketed formulations); investigational cream formulations of roflumilast 0·5% and TAK-084 0·5% and 5%; and a vehicle cream formulation as a control. Each treatment was applied daily to different test sites located on psoriasis plaques for 3 weeks. Results The primary end point of (mean) change from baseline in Skin Infiltrate thickness after 3 weeks of treatment showed statistically significant improvements for all treatments: betamethasone valerate cream (−286·9 μm), the selective PDE4 inhibitors roflumilast 0·5% (−237·1 μm) and TAK-084 (0·5% cream, −153·6 μm; 5% cream, −216·7 μm) and calcipotriol 0·005% (−187·7 μm) when compared with vehicle cream control (all P < 0·001). Both the TAK-084 5% and roflumilast 0·5% formulations performed well overall compared with the potent corticosteroid, betamethasone, and were ranked better than the vitamin D analogue calcipotriol. All adverse events were mild or moderate and none was serious. Conclusions Topical treatment with cream formulations of the PDE4 inhibitors roflumilast and TAK-084 reduced inflammation, measured as a change in Skin Infiltrate thickness, and reduced psoriasis severity. Corticosteroid treatments have known systemic and cutaneous side-effects; PDE4 inhibitors could offer an alternative to these and deserve further study.

M Suga - One of the best experts on this subject based on the ideXlab platform.

  • transient monocytic Skin Infiltrate during preleukemic phase of acute myelomonocytic leukemia
    The Japanese journal of clinical hematology, 1990
    Co-Authors: Chikara Sakai, T Takagi, M Oguro, M Suga
    Abstract:

    : An acute myelomonocytic leukemia presenting transient Skin rash during preleukemic phase was described. Following four years of unexplained leukopenia, a generalized exanthema developed and subsequently regressed spontaneously. The Skin biopsy and immunohistochemistry revealed monocytic infiltration into the dermis. Twenty-eight months later, the patient became leukemic and died. The Skin lesions, however, did not occur after leukemic transformation. Probably transient monocytic Skin Infiltrate was a symptom of preleukemia, a stem cell neoplasm manifested by functionally abnormal maturation.